Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah

Abdulrahman A. Housawi, Shazada Junaid S. Qazi, Abdulhalem A. Jan, Rashid A. Osman, Mashil M. Alshamrani, Talal A. AlFaadhel, Fayez F. AlHejaili, Jaffar A. Al-Tawfiq, Ahmed A. Wafa, Abdulmageed E. Hamza, Moustafa A. Hassan, Suliman A. Alharbi, Hamza Albasheer, Majed M. Almohmmdi, Salem A. Alsisi, Michal Mankowski, Joris van de Klundert, Amal M. Alhelal, Fatima H. Sala, Ali KheyamiBader A. Alhomayeed

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients. OBJECTIVES: Compare the state of immunity to SARS-CoV-2 among hemodialysis patients and staff. DESIGN: Cross-sectional study with a prospective follow-up period. SETTING: Hemodialysis centers in Madinah region. PATIENTS AND METHODS: We prospectively tested for SARS-CoV-2 antibodies in dialysis patients using dialysis centers staff as controls. The participants were tested on four occasions when feasible for the presence of anti-SARS-CoV-2 antibodies. We also analyzed factors that might be associated with seropositivity. MAIN OUTCOME MEASURES: SARS-CoV-2 positivity using immunoglobulin G (IgG) levels SAMPLE SIZE: 830 participants, 677 patients and 153 dialysis centers staff as controls. RESULTS: Of the total participants, 325 (257 patients and 68 staff) were positive for SARS-CoV-2 IgG antibodies, for a prevalence of 38.0% and 44.4% among patients and staff, respectively (P=.1379). Participants with a history of COVID-19 or related symptoms were more likely to have positive IgG (P
Original languageEnglish (US)
Pages (from-to)246-251
Number of pages6
JournalAnnals of Saudi Medicine
Volume42
Issue number4
DOIs
StatePublished - Aug 4 2022

ASJC Scopus subject areas

  • Medicine(all)

Cite this